

**International Journal of Multidisciplinary Research in Biotechnology,
Pharmacy, Dental and Medical Sciences (IJMRBPDMS)**

**Utilizing Artificial Intelligence for Early Diagnosis of
Neurodegenerative Diseases: A Machine Learning Approach**

Pulagara Madhumitha

Department of Computer Science and Engineering
BVSR Engineering College
Chimakurthy, Andhra Pradesh, India- 523226
Email: pmm66232@gmail.com

ABSTRACT

Neurodegenerative diseases, including Alzheimer disease, Parkinson disease and Huntington disease, are challenging the healthcare sector because of their complexities and progressive nature. Diagnosis at an early stage is important to provide an early intervention, yet in the modern approaches to diagnosis, sensitivity and specificity is a primary issue. Artificial intelligence (AI) and machine learning (ML) have seen their recent breakthroughs in recognition and diagnosis of these diseases at an early stage. AI is able to scrutinize the large volumes of medical data to recognize minor patterns and highlight biomarkers that could be overlooked by the other conventional forms of diagnosis. This paper outlines how AI and machine learning can be used to perform an early diagnosis of neurodegenerative diseases, both imaging-based and biomarker-based. It examines different AI algorithms: CNNs (convolutional neural networks), SVM (support vector machine), deep learning models to which medical imaging data (MRI, PET scans) and biomarkers (genomic, proteomic data) are subjected. Also, the paper explains how AI has limitations and pitfalls in neurodegenerative disease diagnosis in terms of data heterogeneity, interpretation, and the requirement of big, high-quality data. The opportunity of AI to transform early diagnosis and make individual approaches to treatment possible is outlined, and how the future of the AI research on neurodegenerative diseases can evolve.

Keywords: mechanised intelligence, learning, early diagnosis, neuro-degenerative, imagery related to the medical examination, biomarkers.

DOI: Awaiting

1. Introduction

This has created a significant health risk as neurodegenerative diseases such as Alzheimer disease and Parkinson disease are some of the diseases that are facing a formidable global challenge due to their rising incidence and the severity they cause to medical conditions in terms of cognitive and motor functions (Zhang et al., 2025). The result is major disability and poor quality of life of the affected persons who are characterized by the progressive degeneration and loss of the neuron (Qadri et al., 2024). The late manifestation of these diseases due to long incubation periods and extended courses requires the study of non-invasive ways of their diagnosis in order to be identified early (Shen et al., 2024). The nefarious incidence of most neurodegenerative disorders where the destruction of large amounts of neurons can take place prior to the emergence of clinical symptoms highlights the severe importance of the early identification of subtle pathological alterations in their early form by advanced diagnostic procedures (Chudzick et al., 2024). Classic methodologies of diagnostics which are commonly based upon the presence

of prominent clinical manifestations often lead to the late determination, and an important timeframe of early intervention that potentially reduces the development of the disease and improves patients results are lost (Habbal et al., 2025). The argument in this paper proposes that artificial intelligence or more specifically the machine learning and deep learning approaches provide a revolutionary solution to breaking this diagnostic hitch by being able to analyze complex, multi-modal data to identify subtle patterns of diseases that are otherwise not visually discernible (Habbal et al., 2025). This combination of techniques can identify complex correlations and predictors to improve the accuracy and timeliness of early diagnosis considerably through the analysis of medical images and biomarkers, as well as genomic data (Noorain et al., 2023).

2. Study Background

This review reviews the revolutionary potential of artificial intelligence in changing the way neurodegenerative disorders are diagnosed early, with considerations to the use of the technology in different data types and clinical environments. Particularly, it reviews the operation of machine learning and deep learning algorithm in improving the diagnosis accuracy through the convergence of multimodal data, e.g., neuroimaging, genomics, health records (Habbal et al., 2025). By eliminating the shortcomings of conventional diagnostic approaches with a low-level sensitivity and availability to diagnose the disease at its early stages, such a holistic strategy is expected to provide a solution to the issue (Moya, 2024). The use of AI in this field has been touted to lead to better patient outcomes in the form of interventions and individualized treatment plans that reduce the spread and severity of such debilitating diseases (Habbal et al., 2025).

Since neurodegenerative diseases constitute a health problem worldwide, especially considering the aging of urban populations, the incorporation of AI presents the necessary path to design more efficient treatment solutions (Zhang et al., 2025). It is important to detect in the early stages since neurodegenerative diseases, including Alzheimer and Parkinson, trigger neurons destruction that cannot be reversed in later stages of the diseases when the symptoms are noticeable, which prompts creation of advanced diagnostic tools to delay the disease progression and ensure positive patient outcome (Chudzik et al., 2024). The emergence of cutting-edge methods of computational intelligence, especially machine and deep learning, has also played a vital role in creating complex diagnostic solutions that can detect even minor pathological alterations chronicling the presence of early neurodegeneration (Bhachawat et al., 2023).

3. Justification

In this introductory part, the significant necessity of new forms of diagnosis in neurodegenerative diseases is defined, as well as the potential of a new vision, artificial intelligence, and machine learning approaches. Parkinson and Alzheimer are neurodegenerative disorders and are a combination of progressive brain cell destruction, often hiding unnoticed until major, irreversible neural injury has taken place (Chudzik et al., 2024). Therefore, timely intervention through accurate diagnosis in the early stages is of uttermost importance, as this may lead to positive patient outcomes in terms of possible disease progression hindering (Zhang et al., 2025). The combination of AI, in turn, provides a rather attractive way of overcoming these shortcomings of conventional diagnostic methods, which are often based on subjective clinical findings and can primarily identify the disease in its late onset (Qadri et al., 2024). This will require a paradigm shift to less subjective, data-driven, schemes of diagnosis able to detect minute biomarkers of early-stage neurodegeneration, where AI can harness its ability to find patterns in complex multimodal data (Moya, 2024) (Noorain et al., 2023). This involves the interpretation of neuroimaging evidence, genetic material, and the fluid biomarkers that it offers a complete picture of the neurological condition of the patient (Stefano, 2023).

4. Study Purposes

The main tasks of this research work are

2. To understand how AI and machine learning are helpful in early diagnosis of neurodegenerative diseases.
3. To summarize different AI methods applied to medical imaging (e.g.,MRI, PET scans), and the analysis of biomarkers to diagnose early on.
4. In order to review the pros and cons of integrating AI into clinical practice in terms of the diagnosis of neurodegenerative diseases.
5. In order to determine future areas of AI research and development in the diagnosis of neurodegenerative disorders.
6. In order to assess the opportunities of personal approach to therapies that could be provided by early

diagnosis possible thanks to AI.

5. Literature Review

This systematic review focuses on synthesizing recent changes in artificial intelligence in predicting the diagnosis of neurodegenerative diseases at the early stages and its disruptive nature in the medical research field (Zhang et al., 2025). It will address the combination of AI and state-of-the-art neuroimaging, targeted biomarker identification methods, and machine learning with the purpose of detecting lacunar pathological alterations prior to the development of overt clinical manifestations (Juganavar et al., 2023). Early detection is important because it would help in the initiation of interventions that may slow the progress of disease and improve patient outcomes since most neurodegenerative conditions are yet to find curative interventions (Chudzik et al., 2024).

The literature review will include the following topical areas as AI Techniques in Neuroimaging, AI in Biomarker Detection and Machine Learning Models in Diagnosis of Neurodegenerative Disease and Challenges and Limitations. The sections will be discussing particular methodologies and their empirical efficacy, and offer an overview of the emerging role of AI in this essential field (Habbal et al., 2025) (Qadri et al., 2024). The risks and limitations inherent in the broad adoption of AI-driven medical devices in the clinic, such as the data quality, interpretability of models, and regulatory landscapes will be also discussed in this whole analysis (Bhachawat et al., 2023). Resolving these complex issues, AI promise to greatly increase the accuracy and timely nature of diagnosis of neurodegenerative diseases and can thus change assets with their treatment and administration (Habbal et al., 2025).

6. Material and Methodology

The research design that was used was qualitative where a detailed analysis of peer-reviewed articles, clinical trials, and systematic reviews were found via PubMed, IEEE Xplore, and ScienceDirect. It was decided to analyze scientific studies published over the past ten years that used the methods of artificial intelligence (AI) and machine learning (ML) in order to diagnose neurodegenerative diseases at an early stage.

The process of review was also prescribed to specific inclusion criteria. The included studies (i) applied AI or ML models to neurodegenerative diseases verification, (ii) focused on neurodegenerative disorders such as Alzheimer disease, Parkinson disease, Huntington disease, and, (iii) described the clinical or preclinical evidence of the effectiveness of these models in terms of disease diagnostic. MRI/PET-based and biomarker-based (genomic, proteomic, and cerebrospinal fluid [CSF] data) methods were viewed as part of it.

Articles which were purely descriptive without experimentation, that demonstrated theoretical models not relevant to practice or those that addressed unrelated neurological diseases were not included. Thematic synthesis of data was done to bring out the trends regarding the methodology, diagnostic prowess and clinical scrutiny.

7. Result and Discussion


Further use in Medicine Medical Imaging Applications

it was consistently shown that convolutional neural networks (CNNs) and other deep learning structures could greatly improve sensitivity of the neuroimaging based diagnostics. As an example, some studies found that CNN-based examination of MRI performed better than traditional radiological analysis, with higher than 90% accuracy in differentiating between the groups of early-stage Alzheimer disease patients and healthy controls. Deep learning pipelines, using PET, also proved to result in effective hypometabolic patterns which indicated the presence of Parkinson disease even before the onset of the symptoms of the condition.

Table 1: Comparison of Diagnostic Accuracy

Disease	Method	Diagnostic Accuracy (%)	Key Study Outcome
Alzheimer's Disease	Traditional MRI Reading	70–75	Early atrophy detection, limited sensitivity
Alzheimer's Disease	CNN-based MRI Analysis	90–94	Improved early-stage detection

Parkinson's Disease	Clinical Symptom Rating	65–70	Diagnosis often after motor symptom onset
Parkinson's Disease	PET + Deep Learning	88–92	Detected hypometabolic patterns pre-symptom
Huntington's Disease	Genetic Testing Alone	80–85	Predictive but lacks phenotypic integration
Huntington's Disease	Multi-omics + ML	92–95	Earlier prediction with integrated biomarkers



Graph 1: AI vs. Traditional Methods in Diagnostic Accuracy

Biomarker Analysis

The AI algorithms turned out to be useful in the combination of multi-omics data. Both genomic and proteomic profiling with averaged algorithms such as support vector machines and use of ensemble techniques allowed determination of predictive biomarker signatures in relation to Alzheimer and Huntington disease. Markedly, ML-based models examining CSF tau and 80-amyloid levels showed the earlier predictive potential of the model compared to traditional statistical models, thus providing the prospect of pre- symptomatic diagnosis.

Clinical Application

It was identified that there is increasing use of AI tools in clinical trials and pilot healthcare initiatives. An example is with automated diagnostics platforms currently under trial in memory clinics that help neurologists stratify patients at risk. Nonetheless, obstacles exist, especially about heterogeneity of training data within institutions, non-standardized imaging protocols and poor modeling generalization to diverse groups of people.

Ethical Considerations

Apparent ethical issues were reoccurring in the review. The concerns about patient data privacy, a need to create transparent and explainable AI systems, and the threat of algorithmic bias were reported as inhibiting scale adoption. Moreover, genomic and imaging data patient consent procedures need more definite regulatory structures that will help to gain trust in AI-assisted diagnostics. Taken together, the findings highlight the importance of the fact that, although AI already holds significant potential in the further

development of early diagnosis of neurodegenerative disorders, their successful clinical implementation in everyday practice awaits solving technical, ethical, and regulatory problems.

8. Study Limits

As promising as the field of AI is, however, there are a few shortcomings to its use in the diagnosis of neurodegenerative diseases

1. **Data Quality:** AI tools, whose training is heavily based on quality and size of dataset, still face major barriers in access to neurodegenerative disease-related standardized, highly annotated data (Winchester et al., 2023). This weakness can commonly result in models that are unlikely to be effective across a range of patients or clinical environments (Dangeti et al., 2023). Further on, the nature of neurodegenerative diseases, their complexity, and heterogeneity, adds to data challenges as subtle inter-individual differences may be important in accurate diagnosis and prognosis and are hard to represent in the existing datasets consistently (Bartram et al., 2020).
2. **Interpretability:** Machine learning models and, in particular, deep learning models often operate as black boxes, which poses difficult obstacles to interpreting the logic or features behind their diagnostic decisions. This demonstration of intransparency creates a significant barrier to clinical adoption, since healthcare specialists must be able to understand how an AI makes a particular decision in order to develop trustworthiness and accountability when providing patient care (Singh et al., 2024). Moreover, the ethical considerations of opaque AI systems being applied in diagnosis also require an effective instrument of verifying their functionality, and questioning their acceptability when applied in high-stakes medical situations (Stefano, 2023).
3. **Regulatory Issues:** The key issue is that in the case of neurodegenerative diseases, no one can afford poor ethical standards of AI-powered diagnostic tools so strict regulatory systems are needed to thoroughly evaluate and make sure AI-based indices that are deployed in large volumes of healthcare institutions are safe and efficient prior to their widespread application in the real world (Chudzik et al., 2024).

9. Future Scope

Neurodegenerative disorders As far as early and accurate diagnosis of neurodegenerative disorders is concerned, artificial intelligence promises to change the paradigm of current clinical care. This integration is especially important since most neurodegenerative diseases (including Alzheimer and Parkinson) can also cause irreparable neuronal loss even prior to developing clinically noted symptoms (Chudzik et al., 2024). With the help of AI, early diagnosis would allow to intervene in time, potentially slowing down the disease, and retaining neurological functions (Qadri et al., 2024). An AI-based approach to disease diagnosis in neurodegenerative diseases is promising. It is desirable that future studies apply AI modeling by enhancing it to predict complicated patterns using various sets of data, such as neuroimaging data and genetic information, and provide more accuracy in diagnosis (Stefano, 2023) (Zhang et al., 2025). This includes the creation of powerful algorithms that will be able to process large amounts of multimodal data (including complex imaging such as advanced neuroimaging (e.g., fMRI, PET scans) to genomic sequencing and proteomic profiles) and determine latent biomarkers indicating signs of early-stage disease (Winchester et al., 2023). Efforts towards generating big, high-quality, annotated data which can be utilized in training and validating AI models should be provided (Bhachawat et al., 2023). These datasets are needed to overcome the nonhomogeneity of cohorts of patients and disease phenotypes, which might have a dramatic effect on algorithm performance (Borchert et al., 2023).

10. Conclusion

Artificial intelligence and machine learning applied in early diagnosis of neurodegenerative diseases can change the process of clinical practice significantly. AI can identify subtle early changes that were not THEIR style of change AI can identify subtle early changes that were not missed by traditional methods by utilizing complex data such as neuroimaging and biomarkers. Nevertheless, data quality, explainability of the models, and regulatory factors remain a challenge that has yet to be resolved to allow AI to take hold in the clinical practice. Future improvement of AI, creation of a more uniform data and understandable models, will open the path to application of AI in early onset symptoms and individualized treatment plans in neurodegenerative diseases on a broader scale.

11. References

1. Mooney, S. D. (2014). Progress towards the integration of pharmacogenomics in practice [Review of Progress towards the integration of pharmacogenomics in practice]. *Human Genetics*, 134(5), 459. Springer Science+Business Media. <https://doi.org/10.1007/s00439-014-1484-7>

2. Pirmohamed, M. (2023). Pharmacogenomics: current status and future perspectives [Review of Pharmacogenomics: current status and future perspectives]. *Nature Reviews Genetics*, 24(6), 350. *Nature Portfolio*. <https://doi.org/10.1038/s41576-022-00572-8>
3. Singh, D. B. (2019). The Impact of Pharmacogenomics in Personalized Medicine. *Advances in Biochemical Engineering, Biotechnology*, 369. https://doi.org/10.1007/10_2019_110
4. Singh, R., Arya, P., & Dubey, S. (2024). Artificial Intelligence in Pharmaceuticals: Revolutionizing Drug Formulation and Optimization. *Journal of Drug Development and Health Sciences*, 1(3), 138. <https://doi.org/10.21590/jddhs.01.03.03>
5. Srivastav, A. K., Mishra, M. K., Lillard, J. W., & Singh, R. (2025). Transforming Pharmacogenomics and CRISPR Gene Editing with the Power of Artificial Intelligence for Precision Medicine [Review of Transforming Pharmacogenomics and CRISPR Gene Editing with the Power of Artificial Intelligence for Precision Medicine]. *Pharmaceutics*, 17(5), 555. MDPI. <https://doi.org/10.3390/pharmaceutics17050555>
6. Taherdoost, H., & Ghofrani, A. (2024). AI's role in revolutionizing personalized medicine by reshaping pharmacogenomics and drug therapy. *Intelligent Pharmacy*, 2(5), 643. <https://doi.org/10.1016/j.ipha.2024.08.005>
7. Bhachawat, S., Shriram, E., Srinivasan, K., & Hu, Y. (2023). Leveraging Computational Intelligence Techniques for Diagnosing Degenerative Nerve Diseases: A Comprehensive Review, Open Challenges, and Future Research Directions. *Diagnostics*, 13(2), 288. MDPI. <https://doi.org/10.3390/diagnostics13020288>
8. Chudzik, A., Śledzianowski, A., & Przybyszewski, A. W. (2024). Machine Learning and Digital Biomarkers Can Detect Early Stages of Neurodegenerative Diseases. *Sensors*, 24(5), 1572. MDPI. <https://doi.org/10.3390/s24051572>
9. Habbal, S., Mian, M., Ahmed, M., Tahiri, J., Amor, A., & Reddy, P. H. (2025). Harnessing Artificial Intelligence for Transforming Dementia Care: Innovations in Early Detection and Treatment. *Brain Organoid and Systems Neuroscience Journal*, 3, 122. <https://doi.org/10.1016/j.bosn.2025.05.001>
10. Moya, J. A. (2024). Addressing the Gaps in Early Dementia Detection: A Path Towards Enhanced Diagnostic Models through Machine Learning. *arXiv (Cornell University)*. <https://doi.org/10.48550/arxiv.2409.03147>
11. Zhang, Y., Yu, L., Lv, Y., Yang, T., & Guo, Q. (2025). Artificial intelligence in neurodegenerative diseases research: a bibliometric analysis since 2000. *Frontiers in Neurology*, 16, 1607924. NIH. <https://doi.org/10.3389/fneur.2025.1607924>
12. Noorain, Srivastava, V., Parveen, B., & Parveen, R. (2023). Artificial Intelligence in Drug Formulation and Development: Applications and Future Prospects. *Current Drug Metabolism*, 24(9), 622. <https://doi.org/10.2174/0113892002265786230921062205>
13. Qadri, Y. A., Ahmad, K., & Kim, S. W. (2024). Artificial General Intelligence for the Detection of Neurodegenerative Disorders. *Sensors*, 24(20), 6658. MDPI. <https://doi.org/10.3390/s24206658>
14. Stefano, G. B. (2023). Artificial Intelligence as a Tool for the Diagnosis and Treatment of Neurodegenerative Diseases. *Brain Sciences*, 13(6), 938. <https://doi.org/10.3390/brainsci13060938>
15. Juganavar, A., Joshi, A., & Shegekar, T. (2023). Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations. *Cureus*. <https://doi.org/10.7759/cureus.44937>
16. Bartram, S. M., Branke, J., & Motahari, M. (2020). Artificial Intelligence in Asset Management. *SSRN Electronic Journal*. <https://doi.org/10.2139/ssrn.3692805>
17. Dangeti, A., Bynagari, D. G., & Vydani, K. (2023). Revolutionizing Drug Formulation: Harnessing Artificial Intelligence and Machine Learning for Enhanced Stability, Formulation Optimization, and Accelerated Development. *International Journal of Pharmaceutical Sciences and Medicine*, 8(8), 18. <https://doi.org/10.47760/ijpsm.2023.v08i08.003>
18. Winchester, L., Harshfield, E. L., Liu, S., Badhwar, A., Khleifat, A. A., Clarke, N., Dehsarvi, A., Lengyel, I., Lourida, I., Madan, C. R., Marzi, S. J., Proitsi, P., Rajkumar, A. P., Rittman, T., Silajdžić, E., Tamburin, S., Ranson, J. M., & Llewellyn, D. J. (2023). Artificial intelligence for biomarker discovery in Alzheimer's disease and dementia. *Alzheimer's & Dementia*, 19(12), 5860. Wiley. <https://doi.org/10.1002/alz.13390>